NeuroSense Therapeutics
significantly attenuated disease progression by in | NeuroSense Therapeutics
Company
Deck Type
Sector
Industry
Deck date
December 2023
Slide
17 of 33
Similar slides by NeuroSense Therapeutics
See diffirences between slides (animation)
Investor Presentation
January 2024
slow vital capacity observed a decrease in patients treated with placebo | NeuroSense Therapeutics
Investor Presentation
January 2024
attenuated disease progression by difference in | NeuroSense Therapeutics
Investor Presentation
January 2024
attenuated slow vital capacity by wass | NeuroSense Therapeutics
Investor Presentation
January 2024
significantly attenuated disease progression by in phase study results per protocol population analysis | NeuroSense Therapeutics
Related slides by other companies
Fusion Pharmaceuticals
Investor Presentation
January 2024
program milestones patients | Fusion Pharmaceuticals
MindMed
Investor Presentation
January 2025
regulatory elements supporting filing requirements | MindMed
RenovoRx
IPO
August 2021
designed for success one phase trial to approval pivotal tiger pac phase study schema currently enrolling | RenovoRx
Dare Bioscience
Investor Presentation
February 2023
dar working to accelerate innovation in women health upcoming program milestones dare | Dare Bioscience
Other recent decks by NeuroSense Therapeutics
See all presentations (4 decks)
Investor Presentation
October 2024
Investor Presentation
January 2024
Investor Presentation
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights